TY - JOUR T1 - A comprehensive antigen production and characterization study for easy-to-implement, highly specific and quantitative SARS-CoV-2 antibody assays JF - medRxiv DO - 10.1101/2021.01.19.21249921 SP - 2021.01.19.21249921 AU - Miriam Klausberger AU - Mark Dürkop AU - Helmuth Haslacher AU - Gordana Wozniak-Knopp AU - Monika Cserjan-Puschmann AU - Thomas Perkmann AU - Nico Lingg AU - Patricia Pereira Aguilar AU - Elisabeth Laurent AU - Jelle De Vos AU - Manuela Hofer AU - Barbara Holzer AU - Maria Stadler AU - Gabriele Manhart AU - Klemens Vierlinger AU - Margot Egger AU - Lisa Milchram AU - Elisabeth Gludovacz AU - Nicolas Marx AU - Christoph Köppl AU - Christopher Tauer AU - Jürgen Beck AU - Daniel Maresch AU - Clemens Grünwald-Gruber AU - Florian Strobl AU - Peter Satzer AU - Gerhard Stadlmayr AU - Ulrike Vavra AU - Jasmin Huber AU - Markus Wahrmann AU - Farsad Eskandary AU - Marie-Kathrin Breyer AU - Daniela Sieghart AU - Peter Quehenberger AU - Gerda Leitner AU - Robert Strassl AU - Alexander E. Egger AU - Christian Irsara AU - Andrea Griesmacher AU - Gregor Hoermann AU - Günter Weiss AU - Rosa Bellmann-Weiler AU - Judith Loeffler-Ragg AU - Nicole Borth AU - Richard Strasser AU - Alois Jungbauer AU - Rainer Hahn AU - Jürgen Mairhofer AU - Boris Hartmann AU - Nikolaus B. Binder AU - Gerald Striedner AU - Lukas Mach AU - Andreas Weinhäusl AU - Benjamin Dieplinger AU - Florian Grebien AU - Wilhelm Gerner AU - Christoph J. Binder AU - Reingard Grabherr Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/20/2021.01.19.21249921.abstract N2 - Antibody tests are essential tools to investigate humoral immunity following SARS-CoV-2 infection. While first-generation antibody tests have primarily provided qualitative results with low specificity, accurate seroprevalence studies and tracking of antibody levels over time require highly specific, sensitive and quantitative test setups. Here, we describe two quantitative ELISA antibody tests based on the SARS-CoV-2 spike receptor-binding domain and the nucleocapsid protein. Comparative expression in bacterial, insect, mammalian and plant-based platforms enabled the identification of new antigen designs with superior quality and high suitability as diagnostic reagents. Both tests scored excellently in clinical validations with multi-centric specificity and sensitivity cohorts and showed unprecedented correlation with SARS-CoV-2 neutralization titers. Orthogonal testing increased assay specificity to 99.8%, thereby enabling robust serodiagnosis in low-prevalence settings. The inclusion of a calibrator permits accurate quantitative monitoring of antibody concentrations in samples collected at different time points during the acute and convalescent phase of COVID-19.Competing Interest StatementAll authors declare no conflict of interest but J.M. and G.S. owns an interest in enGenes Biotech GmbH, the legal entity commercializing the enGenes-X-press technology and the antigens developed within this work. C.B is a board member of Technoclone. N.B. is employee of Technoclone. P.Q. is Advisory Board Member for Roche Austria, and reports personal fees from Takeda.Clinical TrialN/A (not a prospective clinical trial)Funding StatementWe thank the Vienna Science and Technology Fund (WWTF) for partial funding of this project (Project No. COV20-016). We thank the University of Natural Resources and Life Sciences (BOKU) Vienna, the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology and the Ludwig Boltzmann Gesellschaft for financial support of the project. Jelle De Vos acknowledges the Research Foundation Flanders (FWO) for support by grants 12J6520N and V443719N, and the OEAD (Austria) for scholarship ICM-2019-14929. FFG. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study includes work with human sera from three different sites. Acute lithium heparin plasma samples collected from outpatient and hospitalized individuals for routine clinical testing were available at the B&S Central Laboratory Linz, Austria. Left-over samples were assessed for SARS-CoV-2 antibody levels and neutralizing titers in the early phase of infection and the study protocol was approved by the ethics committee of Upper Austria (EK1083/2020), in accordance with the Declaration of Helsinki. For ELISA validations, left-over sera from SARS-CoV-2 patients and sera from convalescent donors, as well as historical sera (<2020) were taken from the MedUni Wien Biobank, as approved by the ethics committee of the Medical University of Vienna (EK 1424/2020). The underlying sample collections were reviewed and approved by the ethics committee of the Medical University of Vienna (EK 595/2005, EK 404/2011, EK 518/2011), or by the ethics committee of the City of Vienna (EK-11-117-0711), respectively. Samples from hospitalized COVID-19 patients at the University Hospital of Innsbruck, reconvalescent COVID-19 patients with persistent cardio-pulmonary damage participating in a prospective observational study (CovILD-study, ClinicalTrials.gov number, NCT04416100, Reference: PMID: 33303539) and reconvalescent persons volunteering as plasma donors were used for test validation in Innsbruck66. The underlying sample collections were reviewed and approved by the ethics committee of the Medical University of Innsbruck (EK 1103/2020, EK 1167/2020). Left-over SARS-CoV-2 acute and convalescent sera from blood donors and pre-COVID-19 sera from the Austrian Institute of Technology were taken for SARS-CoV-2 antigen pre-validation and the study was approved by the ethics committee of the city of Vienna (EK 20-179-0820).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and study protocol can be requested from the corresponding authors by interested researchers. ER -